Liver metabolic abnormalities in obese patients infected with COVID-19
DOI:
https://doi.org/10.52556/2587-3873.2024.5(102).25Keywords:
COVID-19 viral infection, obesity, body massindex (BMI), cytolysis syndrome, FIB-4 test, lipid spectrumAbstract
Obese individuals were twice as likely to develop COVID-19 and complications, To study lipid metabolism:cholesterol (CH), triglycerides (TG) and liver functional state,by studying the cytolysis syndrome Alaninaminotransferase (ALAT), aspartataminotranspeptidase (ASAT), Fib-4 test indicators, in obese patients infected with SARS-CoV-2. There were examined 44 patients: 27 men(61.62%), 17 women (38.8%). The average age was 55.16±4.5years.The degree of obesity was evaluated by BMI the ratio of body weight in kilograms to the square of height in meters (kg/m2). All patients were divided into 4 groups according to BMI: I gr. (n=9) BMI=30-34.9 kg/ m², II gr. (n=8) BMI=35-39.9 kg/m², III gr. (n=10), BMI>40 kg/m². Comparison group IV(CG) patients (n=17) infected with COVID-19, normal weight. The maximum increase în patients III gr. BMI>40 . ALAT: 64.3±6,2 u/l, p≤0.05, in gr.II-48.3±3.2 u/l, p≤0.05, in gr.I-44±3,2 u/l, p≥0.05 and controlgr.-40,3±2,4 u/l. The ASAT level in patients with gr. III was 55.2±5.3 u/l, p≤0.01, in gr. II-48.2±4,4 u/l, p≤0.01, in gr.I-44,2±3.4 u/l p≤0.05, in CG-34.8±1,7 u/l. Lipid spectrum: the maximum increase in TG levels was detected in III gr.-1,92±0.3 mmol/l, p≤0.05, in II gr.-1,88±0.3 mmol/l, p≤0.05, in 1 gr.-1.68±0.2 mmol/l, p≤0.05, compared to the CG-1.0±0.2 mmol/l. At III gr. there was a tendency to reduce the level of CH in the blood serum 3.9±0.2 mmol/l p≤0.001, in gr. II- 4.2±0.2 mmol/l p≤0.01 in gr. I-4.5±0.1 mmol/l p≤0.01 and to the control group-5.5±0.3 mmol/l. The Fib-4 index maximum,values were found in group III-2.07±0,3, in II-1,86±0,3, in gr.1-1,26±0,2,and control gr.–1,34±0,4. In group III, patients with BMI >40 kg/m² had marked disorders of lipid metabolism and liver function compared to patients in groups I, II and controls.
References
1. GAO, F., ZHENG, K.I., WANG, X.B., et al. Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients. In: Gastroenterol. Hepatol. 2021, nr. 36 (1), pp. 204-207. ISBN: 10.1111/jgh.15112. https://doi.org/10.1111/jgh.15112
2. MICHALAKIS, D., GOULIS, A. et al Obesity in the ageing man. In: Metabolism. 2013, nr. 62, pp. 1341-1349. https://doi.org/10.1016/j.metabol.2013.05.019
3. DIVELLA, R., DE LUCA, I., ABBATE, E. et al Obesity and cancer: the role of adipose tissue and adipocytokines-induced chronic inflammation. In: Cancer. 2016, nr. 7(15), pp. 2346-2359. https://doi.org/10.7150/jca.16884
4. ELLULU, I., PATIMAH, H., KHAZA'AI, A. et al Obesity and inflammation: the linking mechanism and the complications. In: Arch. Med. Sci. 2017, nr. 13(4), pp. 851-863 https://doi.org/10.5114/aoms.2016.58928
5. GAO, F., ZHENG, K., WANG, X/B. et al. Obesity is a risk factor for greater COVID-19 severity. In: Diabetes Care 2020, nr. 43, e72-e74 https://doi.org/10.2337/dc20-0682
6. CAI, Q., HUANG, D., YU, H. et al. Characteristics of liver tests in COVID-19 patients. In: J, Hepatol. 2020.
7. CUROCICHIN, G.H., ŞALARU, V.,GÎȚU, L. Protocolul clinic standardizet pentru medicii de familie. Infecția cu coronavirus de tip nou COVID-19. Pentru aplicare în cazul desfăşurării Scenariului 3 din Planul de pregătire şi răspuns, la infecţia cu coronavirus de tip nou COVID-19. Chişinău, 2020; 6 p.
8. Mc PHERSON, S., STEWART, S.F., HENDERSON, E., BURT, A.D. Simple noninvasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. In: Gut. 2010, nr. 59, pp. 1265-1269 https://doi.org/10.1136/gut.2010.216077
9. LIGHTER, J., PHILLIPS, M., HOCHMAN, S. et al. Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission. In: Clin. Infect. Dis. 2020, nr. 71(15), pp. 896-7. https://doi.org/10.1093/cid/ciaa415
10. MASANA, L., CORREIG, E., IBARRETXE, D., et al. Low HDL and high triglycerides predict COVID-19 severity. In: Scientific Reports. 2021, nr. 11(7217), pp. 1-9.
11. XIAO, J., LI, W., ZHENG, X., QI, L. et al. Targeting 7-Dehydrocholesterol Reductase Integrates Cholesterol Metabolism and Irf3 Activation to Eliminate Infection. In: Immunity. 2020, nr. 52(1), pp. 109-122 https://doi.org/10.1016/j.immuni.2019.11.015
12. HILSER, J.R., HAN, Y., BISWAS, S. et al. Association of Serum Hdl-Cholesterol and Apolipoprotein A1 Levels With Risk of Severe Sars-CoV-2 Infection. In: J. Lipid. Res. 2021, nr. 62. https://doi.org/10.1016/j.jlr.2021.100061
13. REZAEI, A., NESHAT, S., HESHMAT-GHAHDARIJANI, K. Alterations of Lipid Profile in Covid-19: A Narrative Review. In: Curr. Probl. Cardiol. 2022, nr. 47(3) https://doi.org/10.1016/j.cpcardiol.2021.100907
14. VAN ROOYEN, D., LARTER, Z., HAIGH, W., et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. In: Gastroenterology. 2011, nr. 141(4), pp. 1393-1403 https://doi.org/10.1053/j.gastro.2011.06.040
15. DAVIDOV-DEREVYNKO, Y., BEN YAKOV, G., WIEDER, A. et al. The liver in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In: Eur J Gastroenterol Hepatol. 2021, nr. 33(1S), e313-e319 https://doi.org/10.1097/MEG.0000000000002048
16. SUDHAKAR S., WINFRED G.,MEIYAZHAGAN et al. Mechanisms contributing to adverse outcomes of COVID-19 in obesity. Molecular and Cellular Biochemistry 2022 Apr;477(4):1155-1193. https://doi.org/10.1007/s11010-022-04356-w
17. SARMADI, M., AHMADI-SOLEIMANI, M. et al. COVID-19, body mass index and cholesterol: an ecological study using global data. In: Public Health 2021, nr. 21(1) https://doi.org/10.1186/s12889-021-11715-7
18. KARASEVA, A., EVDOKIMOVA, N. et al. Associations of changes in lipid metabolism parameters and the severity of COVID-19 infection in Novosibirsk residents. In: Russian Journal of Cardiology. 2022, nr. 27(9). https://doi.org/10.15829/1560-4071-2022-4979
19. TIGNANELLI, C., BRAMANTE, C., DUTTA, N. et al. Metabolic surgery may protect against admission for COVID-19 in persons with nonalcoholic fatty liver disease. In: Surg. Obes. Relat. Dis. 2021, nr. 17(10), pp. 1780-1786 https://doi.org/10.1016/j.soard.2021.05.029
20. CHAI, X., HU, L., ZHANG, Y., HAN, W., LU, Z., KE, A. et al Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. In: bioRxiv 2020, 13. p. https://doi.org/10.1101/2020.02.03.931766
21. YKI-JARVINEN, H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. In: Lancet Diabetes Endocrinol. 2014, nr. 2(11), pp. 901-910. https://doi.org/10.1016/S2213-8587(14)70032-4
22. BARKER, G., LEEUWENBURGH, C., BRUSKO, T. et al Lipid and Lipoprotein Dysregulation in Sepsis: Clinical and Mechanistic Insights into Chronic Critical Illness. In: J. Clin. Med. 2021, nr. 10(8): 1693. https://doi.org/10.3390/jcm10081693
23. KOČAR, E., REŽEN, T., ROZMAN, D. Cholesterol, Lipoproteins, and Covid-19: Basic Concepts and Clinical Applications. In: Biochimica et biophysica acta. Molecular and cell biology of lipids. 2021, nr. 1866(2):158849. https://doi.org/10.1016/j.bbalip.2020.158849
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
